Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medifast (MED) EBITDA Margin (2016 - 2025)

Medifast's EBITDA Margin history spans 16 years, with the latest figure at 10.39% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1099.0% year-over-year to 10.39%; the TTM value through Dec 2025 reached 3.68%, down 416.0%, while the annual FY2025 figure was 3.68%, 416.0% down from the prior year.
  • EBITDA Margin reached 10.39% in Q4 2025 per MED's latest filing, down from 4.56% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 15.58% in Q2 2021 to a low of 10.39% in Q4 2025.
  • Average EBITDA Margin over 5 years is 6.57%, with a median of 10.23% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: crashed -1774bps in 2024, then soared 366bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 12.4% in 2021, then fell by -22bps to 9.67% in 2022, then tumbled by -53bps to 4.54% in 2023, then plummeted by -87bps to 0.6% in 2024, then tumbled by -1844bps to 10.39% in 2025.
  • Per Business Quant, the three most recent readings for MED's EBITDA Margin are 10.39% (Q4 2025), 4.56% (Q3 2025), and 1.01% (Q2 2025).